PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: A meta-analysis

5Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We conducted this meta-analysis to compare the efficacy and safety of PARP inhibitors with or without chemotherapy versus chemotherapy alone for advanced breast cancer. Methods: A meta-analysis and trial sequential analysis were performed using RevMan 5.2 analysis software. Results: Six eligible randomized clinical trials involving 2080 patients were included. Regimens containing PARP inhibitors were significantly associated with higher objective response rate, longer progression-free survival and overall survival. The PARP inhibitor regimen group had a significantly higher rate of grade ≥3 thrombocytopenia than the chemotherapy-only group. Conclusion: Regimens containing PARP inhibitors are effective and safe for BRCA-mutated advanced breast cancer patients. The efficacy appears to be only marginal in patients with BRCA status unselected.

References Powered by Scopus

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

53020Citations
N/AReaders
Get full text

Cancer statistics, 2019

17477Citations
N/AReaders
Get full text

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

4202Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer

8Citations
N/AReaders
Get full text

Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins

2Citations
N/AReaders
Get full text

Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes

2Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yan, F., Jiang, Q., He, M., & Shen, P. (2021). PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: A meta-analysis. Future Oncology, 17(18), 2381–2393. https://doi.org/10.2217/fon-2020-1175

Readers' Seniority

Tooltip

Professor / Associate Prof. 1

33%

Lecturer / Post doc 1

33%

PhD / Post grad / Masters / Doc 1

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

38%

Immunology and Microbiology 2

25%

Business, Management and Accounting 2

25%

Nursing and Health Professions 1

13%

Save time finding and organizing research with Mendeley

Sign up for free